EGFR and neoplasm: When primary tumor size was classified in 5 groups (≤2, 2.01–3, 3.01–5, 5.01–7, and >7), there was a trend of lower incidence of EGFR mutations in larger tumors (48.3%, 52.4%, and 40.6%, 14.6%, 18.5%, respectively; P < 0.001) (Fig. 1A).